Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

Patent metadata

Field	Value
Publication number	US-9539260-B2
Application number	US-201213721805-A
Country	US
Kind code	B2
Filing date	Dec 20, 2012
Priority date	Dec 22, 2011
Publication date	Jan 10, 2017
Grant date	Jan 10, 2017

Abstract

The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof,

wherein Y, V, W, U, Q, R 1 , R 5 , R 7 and R 30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

First claim

The invention claimed is:

1. A compound of formula (I)

or a salt thereof, wherein
Y is selected from O or NH;
V is selected from CR 5 or N;
W is selected from CH 2 , or O;
U is selected from N or CH;
Q is selected from N or CR 6 ;
wherein U and Q are not both N;
R 1 is selected from phenyl, pyridyl, pyrimininyl, pyrazinyl, pyridazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, or
—X—R 4
wherein X is selected from C(O), S(O) 2 or CH 2
and
R 4 is selected from C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, cyano-C 1 -C 8 -alkyl, N,N-di-C 1 -C 4 -alkyl-amino-C 1 -C 8 alkyl, C 1 -C 4 -alkyl-sulfonyl-C 1 -C 8 -alkyl, phenyl, heterocyclyl, heterocyclyl-oxy, heterocyclyl-C 1 -C 8 -alkyl, C 3 -C 12 -cycloalkyl, C 3 -C 12 -cycloalkyl-oxy, C 3 -C 12 -cycloalkyl-C 1 -C 8 -alkyl, heteroaryl, heteroaryl-oxy, heteroaryl-C 1 -C 8 -alkyl, hydroxy, C 1 -C 8 -alkoxy, amino, N—C 1 -C 8 -alkyl-amino or N,N-di-C 1 -C 8 -alkyl-amino,
wherein C 1 -C 8 -alkyl in N—C 1 -C 8 -alkyl-amino and in N,N-di-C 1 -C 8 -alkyl-amino may be unsubstituted or substituted by halogen, hydroxy or C 1 -C 4 -alkoxy,
wherein C 3 -C 12 -cycloalkyl in C 3 -C 12 -cycloalkyl and in C 3 -C 12 -cycloalkyl-C 1 -C 8 -alkyl may be unsubstituted or substituted by 1-5 substituents selected from halogen, hydroxy or C 1 -C 4 -alkoxy;
wherein ‘heterocyclyl’ is a 3 to 7 membered saturated or partially unsaturated monocyclic ring system containing 1 to 3 heteroatoms selected from N, O or S, each of which is unsubstituted or substituted by 1-5 substituents selected from oxo, halogen, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkylamino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl or C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl; wherein ‘heterocyclyl’ can be attached at a heteroatom or a carbon atom and where the N and/or S heteroatoms can also optionally be oxidized to various oxidation states,
wherein ‘heteroaryl’ is a 3 to 7 membered fully unsaturated monocyclic ring system containing 1 to 3 heteroatoms selected from N, O or S, or pyrazolo[1,5-a]pyrimidine or imidazo[2,1-b]thiazole, each of which is unsubstituted or substituted by 1-5 substituents selected from halogen, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl or C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl; wherein ‘heteroaryl’ can be attached at a heteroatom or a carbon atom and where the N and/or S heteroatoms can also optionally be oxidized to various oxidation states;
R 6 is selected from hydrogen, halogen, C 1 -C 4 -alkyl, halo-C 1 -C 4 -alkyl, C 1 -C 4 alkoxy, C 1 -C 4 -alkyl-sulfonyl, C 1 -C 4 alkyl-sulfinyl, C 1 -C 4 alkyl-sulfanyl, halo-C 1 -C 4 -alkoxy, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino;
R 7 is selected from hydrogen, halogen, cyano, nitro, C 1 -C 4 -alkyl, halo-C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, N(R 8 ) 2 -sulfonyl, C 1 -C 4 -alkyl-sulfonyl, C 1 -C 4 -alkyl-sulfonyl-amino, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, or N,N-di-C 1 -C 8 -alkyl-amino;
or R 6 and R 7 , together are CH═CH—CH═CH,
wherein R 8 is independently selected from hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy or two R 8 together with the nitrogen they are attached to form a 4 to 7 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O, S, which is unsubstituted or substituted by 1-3 substituents selected from C 1 -C 4 -alkyl;
R 5 is independently selected from H, D, F or C 1 -C 2 -alkyl;
R 30 is independently selected from H, D or F.

2. A compound according to claim 1 or a salt thereof, of the formula (Ic′)

3. A compound according to claim 1 or a salt thereof, of the formula (Id′)

4. A compound according claim 1 or a salt thereof, of the formula (Ie′)

5. A compound according claim 2 or a salt thereof, of the formula (Ie′)

6. A compound according to claim 1 or a salt thereof, of the formula (If′)

7. A compound according to claim 3 or a salt thereof, of the formula (If′)

8. A compound according to claim 1 or a salt thereof, wherein
R 1 is selected from phenyl, pyridyl, pyrimininyl, pyrazinyl, pyridazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, or
—X—R 4 , wherein
R 4 is selected from C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, cyano-C 1 -C 8 -alkyl, N,N-di-C 1 -C 4 alkyl-sulfonyl-C 1 -C 8 -alkyl, phenyl, heterocyclyl, heterocyclyl-C 1 -C 8 -alkyl, C 3 -C 12 -cycloalkyl, heteroaryl, heteroaryl-C 1 -C 8 -alkyl, C 1 -C 8 -alkoxy, wherein C 1 -C 8 -alkyl in N,N-di-C 1 -C 8 -alkyl-amino may be unsubstituted or substituted by halogen, hydroxy or C 1 -C 4 -alkoxy,
wherein C 3 -C 12 -cycloalkyl in C 3 -C 12 -cycloalkyl and in C 3 -C 12 -cycloalkyl-C 1 -C 8 -alkyl may be unsubstituted or substituted by halogen, hydroxy or C 1 -C 4 -alkoxy;
wherein ‘heterocyclyl’ is a 3 to 7 membered saturated or partially unsaturated monocyclic ring system containing 1 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1-5 substituents selected from oxo, halogen, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl or C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl; wherein ‘heterocyclyl’ can be attached at a heteroatom or a carbon atom and where the N and/or S heteroatoms can also optionally be oxidized to various oxidation states,
wherein ‘heteroaryl’ is a 3 to 7 membered fully unsaturated monocyclic ring system containing 1 to 3 heteroatoms selected from N, O or S, or pyrazolo[1,5-a]pyrimidine or imidazo[2,1-b]thiazole, each of which is unsubstituted or substituted by 1-5 substituents selected from halogen, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl or C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl; wherein ‘heteroaryl’ can be attached at a heteroatom or a carbon atom and where the N and/or S heteroatoms can also optionally be oxidized to various oxidation states.

9. A compound according to claim 1 or a salt thereof, wherein
R 1 is selected from
—X—R 4 , wherein
R 4 is selec

Assignees

• Novartis Ag

Inventors

• Caravatti Giorgio
• Chamoin Sylvie
• Furet Pascal
• Hogenauer Klemens
• Hurth Konstanze
• Kammertoens Karen
• Lewis Ian
• Moebitz Henrik
• Smith Alexander Baxter
• Soldermann Nicolas
• Wolf Romain
• Zecri Frederic

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title